Belite Bio Balance Sheet Health
Financial Health criteria checks 4/6
Belite Bio has a total shareholder equity of $112.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $115.8M and $3.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$88.16m |
| Equity | US$112.20m |
| Total liabilities | US$3.62m |
| Total assets | US$115.82m |
Recent financial health updates
We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow
Sep 26
We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely
Mar 20We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn
May 03Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans
Aug 01Recent updates
We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow
Sep 26Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?
Jul 03We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely
Mar 20An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued
Jan 10Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 31We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn
May 03Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate
Oct 03Belite Bio receives approval of begin LBS-008 phase 3 trial in China
Sep 16Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.
Aug 22Belite Bio GAAP EPS of -$0.23 beats by $0.05
Aug 12Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans
Aug 01Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment
Jul 19Financial Position Analysis
Short Term Liabilities: BLTE's short term assets ($111.3M) exceed its short term liabilities ($3.6M).
Long Term Liabilities: BLTE has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: BLTE is debt free.
Reducing Debt: BLTE has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if BLTE has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BLTE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.